Edition:
United States

Rockwell Medical Inc (RMTI.OQ)

RMTI.OQ on NASDAQ Stock Exchange Global Market

7.33USD
26 May 2017
Change (% chg)

$-0.15 (-2.01%)
Prev Close
$7.48
Open
$7.46
Day's High
$7.46
Day's Low
$7.23
Volume
21,975
Avg. Vol
79,888
52-wk High
$10.56
52-wk Low
$3.55

Latest Key Developments (Source: Significant Developments)

Rockwell Medical enters into license agreement with ARAM Medical
Tuesday, 16 Aug 2016 08:00am EDT 

Rockwell Medical Inc: Rockwell Medical enters into exclusive license agreement with ARAM Medical to commercialize Triferic® in Saudi Arabia, Egypt and Middle East territories . ARAM will also assume responsibility for all clinical and regulatory expenses for territories . Rockwell retains manufacturing responsibilities for both Triferic and Calcitriol . Commercial product availability expected within about 12 months in Saudi Arabia and 12 to 18 months in Egypt and all other territories . ARAM medical will become exclusive distributor for Triferic and Calcitriol in 13 countries .ARAM will pay to Rockwell upfront licensing fees, a "high double-digit royalty on product sales".  Full Article

Rockwell Medical Inc - qtrly sales were $13.5 mln, or 3.8% higher than Q2 2015
Monday, 8 Aug 2016 04:01pm EDT 

Rockwell Medical Inc :Qtrly sales were $13.5 million, or 3.8% higher than q2 2015..  Full Article

Rockwell Medical Q1 loss per share $0.10
Tuesday, 10 May 2016 04:01pm EDT 

Rockwell Medical Inc : Rockwell Medical reports first quarter results . Qtrly net loss $0.10 per share . Q1 earnings per share view $-0.08, revenue view $15.2 million -- Thomson Reuters I/B/E/S . Q1 loss per share $0.10 .Q1 sales $13.6 million versus $13.9 million.  Full Article

Rockwell Medical enters into license agreement with Wanbang Biopharmaceutical Co., Ltd. to commercialize Triferic® in China
Tuesday, 16 Feb 2016 08:00am EST 

Rockwell Medical Inc:Rockwell Medical enters into exclusive license agreement with wanbang biopharmaceutical co., ltd. to commercialize triferic® in China.Wanbang will become the exclusive distributor for triferic and calcitriol in China for an initial commercial term of 10 years.Agreements with wanbang biopharmaceutical for rights to commercialize triferic and calcitriol for end-stage-renal-disease patients.Will receive from wanbang an upfront fee plus regulatory and revenue milestone payments totaling USD$39 million in aggregate.Rockwell will receive ongoing earnings from product sales of triferic,calcitriol, other additional triferic therapeutic indications.  Full Article

Rockwell Medical announces Triferic phase 3 cruise studies published in nephrology dialysis transplantation
Wednesday, 15 Jul 2015 08:00am EDT 

Rockwell Medical Inc:Announces Triferic phase 3 cruise studies published in nephrology dialysis transplantation.Says both studies successfully met the primary endpoint.Says no serious adverse events or deaths were attributed to triferic.  Full Article

More From Around the Web

Rockwell Medical loses round in U.S. court in proxy fight

A U.S. judge has rejected Rockwell Medical Inc's request to block two investors who have launched a proxy fight against the biopharmaceuticals company from soliciting shareholder votes ahead of its June 1 annual meeting.